无症状早老素-1 E280A携带者的联想记忆与在体脑病理
结果显示FCSRT自由回忆评分与淀粉样蛋白和区域tau病理相关,延迟自由回忆在疾病早期即出现困难,提示FCSRT可用于追踪AD进展。
要点
- 认知未受损的PSEN1 E280A携带者FCSRT自由回忆评分与淀粉样蛋白和tau病理相关。
- 延迟自由回忆困难在疾病轨迹中较早出现,提示可早期追踪AD进展。
- 提示回忆困难仅在携带者接近痴呆发病时出现,与病理进展一致。
核心结论
- 在遗传决定未来必发痴呆的认知未受损个体中,FCSRT评分与AD相关病理的在体标志物相关。
- 自由回忆困难(尤其延迟回忆)在疾病轨迹中较早显现,提示回忆困难仅在携带者接近痴呆发病时出现。
研究设计与样本
- 所有参与者接受匹兹堡化合物B-PET(淀粉样蛋白)、flortaucipir-PET(tau)和认知测试(包括FCSRT的即时和延迟自由及提示回忆评分)。
- 采用线性回归分析FCSRT评分、年龄、平均皮层淀粉样蛋白和区域tau负荷之间的关系。
主要发现
- 认知未受损的突变携带者与非携带者之间的自由回忆和总回忆评分无差异。
- 在携带者中,年龄越大预测自由回忆、延迟自由回忆和总回忆评分越低。
- 在认知受损的携带者中,延迟自由回忆预测更大的淀粉样蛋白负荷和内嗅tau,而即时自由回忆评分越差预测下颞叶和内嗅皮层tau越多。
- 在所有携带者中,自由回忆和总回忆评分越低预测淀粉样蛋白和区域tau病理越重。
临床怎么用
- FCSRT可作为追踪AD疾病进展的有用工具。
- 自由回忆困难(尤其延迟回忆)在疾病早期即出现,提示可用于早期监测。
- 提示回忆困难出现较晚,仅在接近痴呆发病时显现,与病理进展一致。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To determine whether performance on the Free and Cued Selective Reminding Test (FCSRT) is associated with PET in vivo markers of brain pathology and whether it can distinguish those who will develop dementia later in life due to autosomal-dominant Alzheimer disease (AD) from age-matched controls. METHODS: Twenty-four cognitively unimpaired Presenilin-1 E280A carriers (mean age 36 years) and 28 noncarriers (mean age 37 years) underwent Pittsburg compound B-PET (amyloid), flortaucipir-PET (tau), and cognitive testing, including the FCSRT (immediate and delayed free and cued recall scores). Linear regressions were used to examine the relationships among FCSRT scores, age, mean cortical amyloid, and regional tau burden. RESULTS: Free and total recall scores did not differ between cognitively unimpaired mutation carriers and noncarriers. Greater age predicted lower free recall and delayed free and total recall scores in carriers. In cognitively impaired carriers, delayed free recall predicted greater amyloid burden and entorhinal tau, while worse immediate free recall scores predicted greater tau in the inferior temporal and entorhinal cortices. In turn, in all carriers, lower free and total recall scores predicted greater amyloid and regional tau pathology. CONCLUSIONS: FCSRT scores were associated with in vivo markers of AD-related pathology in cognitively unimpaired individuals genetically determined to develop dementia. Difficulties on free recall, particularly delayed recall, were evident earlier in the disease trajectory, while difficulties on cued recall were seen only as carriers neared the onset of dementia, consistent with the pathologic progression of the disease. Findings suggest that the FCSRT can be a useful measure to track disease progression in AD.
引用
- Guzmán-Vélez E, Martínez J, Papp K, et al. Associative memory and in vivo brain pathology in asymptomatic presenilin-1 E280A carriers. Neurology. 2020. PMID: 32611637. doi:10.1212/WNL.0000000000010177
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。